Form 4: Day One Biopharmaceuticals Executive Adam Dubow Acquires Stock Options and Restricted Stock Units

Adam Dubow, General Counsel of Day One Biopharmaceuticals, acquired stock options for 90,000 shares and 59,000 restricted stock units (RSUs) on January 15, 2025, according to a Form 4 filing.

Summary

• Adam Dubow, General Counsel of Day One Biopharmaceuticals, filed a Form 4 indicating changes in beneficial ownership.
• On January 15, 2025, Dubow acquired stock options for 90,000 shares of common stock at an exercise price of $11.87.
• These options vest monthly over 48 months starting February 15, 2025, contingent upon continued service to the Issuer.
• Dubow also acquired 59,000 Restricted Stock Units (RSUs), each representing a right to receive one share of Day One Biopharmaceuticals' common stock upon settlement.
• The RSUs vest quarterly over 16 quarters, starting February 15, 2025, also contingent upon continued service.
• The RSUs do not have an expiration date but are canceled if not vested before the vesting date.

Sentiment

Score: 6

Explanation: Neutral sentiment. This is a standard regulatory filing reflecting executive compensation. It doesn't inherently indicate positive or negative news, but rather provides transparency into insider transactions.

Positives

• The acquisition of stock options and RSUs by a key executive signals confidence in the company's future performance.
• The vesting schedules for both the options and RSUs incentivize long-term commitment from the General Counsel.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules suggest an expectation of continued service and contribution from the executive.

Industry Context

Form 4 filings are standard practice and provide transparency into insider transactions, allowing investors to gauge management's sentiment and alignment with shareholder interests. This is a routine filing and doesn't necessarily indicate a major shift in the company's prospects.

Comparison to Industry Standards

• Stock option and RSU grants are common compensation practices in the biopharmaceutical industry to attract and retain talent.
• Vesting schedules are typically structured to incentivize long-term performance, often over a period of 3-4 years.
• The specific terms of the grants (number of shares, exercise price, vesting schedule) are generally benchmarked against peer companies to ensure competitiveness.

Stakeholder Impact

• Shareholders may view the insider transaction as a sign of confidence in the company's future.
• Employees may be motivated by the fact that executives are incentivized to improve company performance.
• The transaction has no immediate impact on customers, suppliers, or creditors.

Key Dates